New Chief Medical Officer Brings Decades of Oncology Expertise to Immuneering
Immuneering, a clinical-stage oncology company dedicated to developing more effective and better tolerated therapies for cancer patients, is pleased to announce the appointment of Igor Matushansky, MD, PhD, as its new Chief Medical Officer. Dr. Matushansky brings extensive experience in oncology drug development and clinical treatment of cancer patients to Immuneering.
Extensive Background in Oncology
Throughout his career, Dr. Matushansky has held leadership positions in academia and industry, including serving as the Chief Medical Officer at OncoEthix, a biotech company focused on developing novel cancer therapies. Prior to that, he was the Director of the Center for Cancer Research at the National Cancer Institute (NCI), where he oversaw the clinical development of several successful oncology drugs. He has also published over 150 peer-reviewed scientific articles and book chapters.
Updated Data from Phase 2a Trial of IMM-1-104 in Pancreatic Cancer
Immuneering plans to present updated data from its Phase 2a trial of IMM-1-104, a novel immunotherapy for pancreatic cancer, in the second quarter of 2025. Dr. Matushansky’s expertise in oncology drug development will be invaluable as the company prepares to present these data to the scientific community and regulatory agencies.
Impact on Individuals
For individuals diagnosed with pancreatic cancer, the appointment of Dr. Matushansky as Chief Medical Officer at Immuneering brings hope for the development of more effective and better tolerated therapies. Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of just 9%. New and innovative treatments are desperately needed to improve outcomes for patients.
Impact on the World
The appointment of Dr. Matushansky as Chief Medical Officer at Immuneering is a significant development for the oncology community as a whole. His expertise in oncology drug development and clinical treatment of cancer patients will help to advance the field and bring new, effective therapies to market. With the global burden of cancer continuing to increase, the need for innovative treatments has never been greater.
Conclusion
The appointment of Igor Matushansky, MD, PhD, as Chief Medical Officer at Immuneering is a major step forward for the company and the oncology community. Dr. Matushansky’s extensive experience in oncology drug development and clinical treatment of cancer patients will be invaluable as Immuneering prepares to present updated data from its Phase 2a trial of IMM-1-104 in pancreatic cancer. This appointment brings hope for the development of more effective and better tolerated therapies for individuals diagnosed with pancreatic cancer, and will have a significant impact on the global fight against cancer.
- Immuneering appoints Igor Matushansky, MD, PhD, as Chief Medical Officer
- Dr. Matushansky brings extensive experience in oncology drug development and clinical treatment of cancer patients
- Updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer to be presented in Q2 2025
- Impact on individuals: hope for more effective and better tolerated therapies for pancreatic cancer patients
- Impact on the world: significant advancement for the oncology community and the global fight against cancer
